Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CERTOLIZUMAB PEGOL Cause Basal cell carcinoma? 418 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 418 reports of Basal cell carcinoma have been filed in association with CERTOLIZUMAB PEGOL (Cimzia). This represents 0.4% of all adverse event reports for CERTOLIZUMAB PEGOL.

418
Reports of Basal cell carcinoma with CERTOLIZUMAB PEGOL
0.4%
of all CERTOLIZUMAB PEGOL reports
2
Deaths
267
Hospitalizations

How Dangerous Is Basal cell carcinoma From CERTOLIZUMAB PEGOL?

Of the 418 reports, 2 (0.5%) resulted in death, 267 (63.9%) required hospitalization, and 23 (5.5%) were considered life-threatening.

Is Basal cell carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CERTOLIZUMAB PEGOL. However, 418 reports have been filed with the FAERS database.

What Other Side Effects Does CERTOLIZUMAB PEGOL Cause?

Drug ineffective (23,838) Rheumatoid arthritis (17,782) Pain (13,929) Fatigue (11,438) Off label use (10,281) Rash (9,663) Alopecia (9,111) Maternal exposure during pregnancy (9,013) Arthralgia (8,993) Abdominal discomfort (8,615)

What Other Drugs Cause Basal cell carcinoma?

ADALIMUMAB (1,547) INFLIXIMAB (1,340) METHOTREXATE (1,268) RITUXIMAB (1,085) ETANERCEPT (998) ABATACEPT (852) TOCILIZUMAB (761) LENALIDOMIDE (685) HYDROXYCHLOROQUINE (662) LEFLUNOMIDE (657)

Which CERTOLIZUMAB PEGOL Alternatives Have Lower Basal cell carcinoma Risk?

CERTOLIZUMAB PEGOL vs CERTOPARIN CERTOLIZUMAB PEGOL vs CETIRIZINE CERTOLIZUMAB PEGOL vs CETIRIZINE\PSEUDOEPHEDRINE CERTOLIZUMAB PEGOL vs CETRIMIDE CERTOLIZUMAB PEGOL vs CETRORELIX

Related Pages

CERTOLIZUMAB PEGOL Full Profile All Basal cell carcinoma Reports All Drugs Causing Basal cell carcinoma CERTOLIZUMAB PEGOL Demographics